Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
Trading information
Product Name | Afatinib |
CAS No. | 850140-72-6 |
Molecular Formula | C24H25ClFN5O3 |
Molecular Weight | 485.94 |
Appearance | white powder |
Purity | 99.0% |
Package | aluminium foil bag; drum |
Payment Terms | L/C; D/A; D/P; T/T |
Delivery | by air; by ship |
Sample Service
Considering the various needs of buyers, we provide small quantity sample to customers. You are welcomed to contact us for the detailed specifications of our APIs and pharmaceutical intermediates. Customers are also expected to confirm the type of freight transport and payment. Any more question please contact us directly.
Mechanism of action for Afatinib
Afatinib is an irreversible kinase inhibitor and binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) to inhibit tyrosine kinase autophosphorylation. This results in a downregulation of ErbB signalling and subsequent inhibition of proliferation of cell lines expressing wild-type EGFR, selected EGFR exon 19 deletion mutations, or exon 21 L858R mutations. It also inhibited in vitro proliferation of cell lines overexpressing HER2. Overall, tumour growth was inhibited.
Technical Team
Jiangsu Allyrise Pharmaceutical Co., Ltd have a young and innovative technician team with average age of 29 and backgrounds of famous universerties. We have rich experience in lab research and pilot scale experiment, laying the foundation for further personnel cultivation.
Research and Development
Relying on advanced research platform and relative service of China Medicine City, Allyrise have made achievements in areas of antineoplastic, antiviral, diabetes drugs in recent years, with more than 20 kinds of APIs and advanced intermediates magnified in pilotscale experiment. The products are widely sold to famous pharmaceutical companies from around the world. To enhance our research and development level, Allyrise developed close cooperation with foreign pharmaceutical companies in customer synthesis and developing new drugs.